Freenome, Inc. (FRNM)
Freenome, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Brisbane, CA, US. The stock last traded at $9.36, down 5.69% on the session, giving a market capitalisation of $76.4M. On trailing twelve-month figures it carries a trailing P/E of -2.25, a net margin of -50.8%. Its beta of 0.35 implies it has historically moved less than the broad market.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).